Partial-enteral Nutrition for Crohn's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new dietary approach for individuals with Crohn's disease, particularly those starting a new immune-based treatment. The study explores whether a special diet combined with a plant-based nutrition supplement (Kate Farms Peptide 1.5) can improve overall nutrition and health. Participants are divided into two groups: one follows the special diet, while the other follows the diet and takes the supplement. Suitable candidates include those with moderate to severe Crohn's disease who are beginning a new biologic therapy.
As an unphased trial, this study provides a unique opportunity to contribute to innovative dietary research that could enhance treatment options for Crohn's disease.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that you should not use pre or probiotic supplements within 14 days of starting the trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that Kate Farms Peptide 1.5 is generally well-tolerated by patients. This plant-based nutritional supplement is designed to aid individuals with conditions like Crohn's disease by being easy to digest and absorb. It is organic, non-GMO, and gluten-free, reducing the risk of allergic reactions or digestive issues.
Although detailed safety information for this specific formula may not be available, its use in various conditions, including Crohn's disease, suggests broad safety. Patients typically report few side effects, making it a promising option for nutritional support.12345Why are researchers excited about this trial?
Unlike the standard treatments for Crohn's Disease, which often include medications like corticosteroids and immunosuppressants, the new approach involves using Kate Farms Peptide 1.5 as part of a partial-enteral nutrition strategy. This treatment is unique because it provides a peptide-based nutritional formula that is easier to digest and absorb, potentially reducing inflammation without the typical side effects of drugs. Researchers are excited about this approach because it could offer a more natural and gentle way to manage symptoms and improve gut health for patients with Crohn's Disease. By combining the IBD-AID diet with Kate Farms Peptide 1.5, the goal is to enhance nutritional support while potentially reducing reliance on medication.
What evidence suggests that this trial's treatments could be effective for Crohn's disease?
Research has shown that the Kate Farms Peptide 1.5 supplement, which participants in this trial may receive, can aid individuals with Crohn's disease during flare-ups when included in their nutrition plan. In one study, 80% of patients with complex digestive issues fully recovered using a similar nutrition method. Another study found that the supplement improved health outcomes in both children and adults. These results suggest that Kate Farms Peptide 1.5 may effectively support better health during Crohn's disease flares.678910
Are You a Good Fit for This Trial?
Adults with Crohn's disease experiencing a flare and starting new immunologic therapy can join. The trial is for those who need better nutrition intake. Specific eligibility details are not provided, but typically participants must meet certain health criteria.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants follow a novel dietary intervention combining a standardized IBD diet with a pea protein plant-based oral nutrition supplement for Crohn's disease flare management
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Kate Farms Peptide 1.5
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kate Farms Inc
Lead Sponsor
University of Minnesota
Collaborator